Fatma Koc

Fatma Koc

Auto-generated profile, based on publicly available information

Fatma Koc

APC Microbiome Ireland, Cork, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in Macromolecular Materials and Engineering
Verified
Journal Article
Open access
PDF file
EAEsra Altun
Esra Altun
MAMehmet Onur Aydogdu
Mehmet Onur Aydogdu
FKFatma Koc
Fatma Koc
MCMaryam Crabbe‐Mann
Maryam Crabbe‐Mann
Francis BrakoFrancis Brako
Francis Brako
Mohan EdirisingheMohan Edirisinghe
Mohan Edirisinghe
Bacterial cellulose (BC) is a very promising biological material. However, at present its utilization is limited by difficulties in shape forming it. In this Communication, it is shown how this can be overcome by blending it with poly(methylmethacrylate) (PMMA) polymer. BC:PMMA fibers are produced by pressurized gyration of blended BC:PMMA solutions. Subsequently, BC:PMMA bandage‐like scaffolds are generated with different blends. The products are investigated to determine their morphological and chemical features. Cell culture and proliferation tests are performed to obtain information on biocompatibility of the scaffolds.

27 May 2018 in International Wound Journal
Verified
Journal Article
Closed access
PDF file
MAMehmet Onur Aydogdu
Mehmet Onur Aydogdu
EAEsra Altun
Esra Altun
MCMaryam Crabbe‐Mann
Maryam Crabbe‐Mann
Francis BrakoFrancis Brako
Francis Brako
FKFatma Koc
Fatma Koc
MEMohan Edirisinghe
Mohan Edirisinghe

3 September 2020 in Nutrition Bulletin
Verified
Journal Article
Open access
PDF file
FKF. Koç
F. Koç
SMS. Mills
S. Mills
CSC. Strain
C. Strain
RRR. Paul Ross
R. Paul Ross
CSCatherine Stanton
Catherine Stanton
Dietary fibre can be considered an essential macronutrient which feeds our gut microbiota, thus enabling the optimal functioning of this ‘virtual organ’. Recommended daily intakes range from 25 to 38 g/day. However, most individuals fail to reach this target and may consume <50% of the recommended amount. Poor dietary fibre intake is associated with an imbalanced gut microbiota leading to reduced diversity and increased abundance of non‐beneficial microorganisms at the expense of beneficial ones. Inflammation is a recognised physiological effect of such a microbiome structure and is a common denominator in several non‐communicable diseases associated with the Western lifestyle/developed world including obesity, cardiovascular disease, type 2 diabetes and colorectal cancer. Yet increasing dietary fibre intake can reduce risk factors associated with these diseases and may even improve prognosis. Several food manufacturers have now developed strategies to increase the fibre content of foods. However, research gaps still remain. In particular, dietary fibre is composed of various non‐digestible carbohydrates and the exact effect of each of these on the gut microbiota is currently unknown. The links between dietary fibre and disease risk are generally associative. Understanding the biological mechanisms will require deeper insight into the impact of the gut microbiota on health. Furthermore, gut microbiota research has shown significant inter‐individual variation meaning that some individuals may not respond to certain dietary fibres owing to the absence of specific microorganisms. Understanding how the different fibre types influence the microbiota, combined with knowledge of an individual’s microbiota, should lead to fibre‐led, microbiota‐based dietary advice.

2 July 2018 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
EAEsra Altun
Esra Altun
MAMehmet Onur Aydogdu
Mehmet Onur Aydogdu
FKFatma Koc
Fatma Koc
OKOzlem Kutlu
Ozlem Kutlu
DGDevrim Gozuacik
Devrim Gozuacik
Oguzhan GunduzOguzhan Gunduz
Oguzhan Gunduz

27 May 2025 in Food & Function
Verified
Journal Article
Closed access
PDF file
FKFatma Koc
Fatma Koc
MSMerve Sabuncu
Merve Sabuncu
GYGünnur Gülkun Yavuz
Günnur Gülkun Yavuz
GDGamze Düven
Gamze Düven
RAReem Mohamed Khalil Abdo
Reem Mohamed Khalil Abdo
CSCatherine Stanton
Catherine Stanton
Tarhana, a traditional fermented food important to Turkish and Central Asian cuisines, is known for its unique composition of yoghurt, flour, vegetables, and herbs, and its potential health benefits through fermentation. The aim of this study was to evaluate tarhana's potential prebiotic and postbiotic properties using an in vitro colonic fermentation model. We explored how ingredient variations, particularly flour types and fermentation methods, influence gut microbial diversity and metabolite production. Tarhana was prepared using wheat, chickpea, einkorn, and purple potato flours, fermented with baker's yeast (Saccharomyces cerevisiae) or chickpea sourdough. Gut microbial composition and levels of short-chain fatty acids (SCFAs) and branched-chain fatty acids (BCFAs) were analysed following in vitro colonic fermentation. Flour type and fermentation method significantly influenced gut microbial composition and metabolite production. Sourdough-fermented tarhana made with purple potato (q = 1.23 × 10−7), chickpea (q = 1.23 × 10−7), and einkorn (q = 2.51 × 10−7) flours reduced Veillonella levels compared to baker's yeast variants. Sourdough purple potato tarhana also decreased Escherichia–Shigella levels in faecal samples, which were higher in baker's yeast-fermented faecal samples (q = 0.003). SCFA levels, particularly acetate and propionate, were higher in chickpea and purple potato tarhana fermented faecal samples, with sourdough variants showing the strongest effects. Bifidobacterium abundance increased in einkorn sourdough tarhana, while chickpea flour tarhana slightly increased isobutyrate levels. This study demonstrates that specific flour types combined with sourdough fermentation enhance tarhana's functional properties by promoting beneficial microbial shifts and increasing SCFA production. These findings suggest tarhana's potential as a personalized functional food to support gut health, warranting further validation through clinical trials.

1 January 2018 in ACTA Pharmaceutica Sciencia
Verified
Journal Article
Closed access
PDF file
TİTuğba İduğ
Tuğba İduğ
HHHilal Hızlı
Hilal Hızlı
AŞAli Şen
Ali Şen
FKFatma Koç
Fatma Koç